{"id":48984,"date":"2022-09-29T17:02:55","date_gmt":"2022-09-29T15:02:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/"},"modified":"2022-09-29T17:02:55","modified_gmt":"2022-09-29T15:02:55","slug":"astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/","title":{"rendered":"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification"},"content":{"rendered":"
\n

\nFirst commercially available product to utilize AstreAdept, Astrea Bioseparations\u2019 novel nanofiber-based membrane material<\/i>\n<\/p>\n

CAMBRIDGE, England–(BUSINESS WIRE)–Astrea Bioseparations (\u201cAstrea Bio\u201d), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO\u2122 lentiviral vector (LVV) purification technology. Incorporating AstreAdept\u2122, the Company\u2019s proprietary nanofiber material, this novel solution addresses the challenges associated with purifying the large and fragile products used in cell and gene therapy.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe believe that AstreAdept will be a game-changer<\/i>,\u201d explained Astrea Bioseparations\u2019 CEO Terry<\/b> Pizzie<\/b>. \u201cOur approach was to rapidly develop and incorporate this material into the Nereus LentiHERO,<\/sup> a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency]<\/i>.\u201d He added<\/b>, \u201cThis launch also sets the stage for a future where cutting-edge therapies can make it into the hands of patients faster and more affordably than ever.\u201d<\/i>\n<\/p>\n

\nDespite the significant potential of LVV therapeutics, speed of development has been slow due to the lack of fit-for-purpose platforms, with users dependent on outdated and inefficient devices. To overcome these barriers, Astrea Bio is developing uniquely designed products that are easier to use than previous approaches. \u201cHigh yield, combined with rapid purification are now possible by utilizing AstreAdept<\/i>,\u201d explained Mr. Pizzie.<\/b>\n<\/p>\n

\nAstreAdept is a proprietary bioseparations material that utilizes cutting-edge nanofiber technology which enables biologics manufacturers to reduce process times, increase process efficiency, reduce buffer consumption, and consequently improve waste treatment costs. As a result, greener, faster, and more cost-effective bioprocessing workflows are possible.\n<\/p>\n

\nAstrea Bio has been developing purification and separation technologies for more than 30 years, with several products used to manufacture FDA approved treatments. Nereus LentiHERO represents the first tool in the Company\u2019s rapidly expanding toolbox of next-generation fit-for-purpose solutions for cell and gene therapy development and manufacturing.\n<\/p>\n

\nFor further information about Astrea Bioseparations, please visit: https:\/\/www.astreabioseparations.com\/<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information please contact:<\/b>
Zyme Communications
\n
Lily Jeffery
\n
Tel: +44 (0) 7891 477378
\n
Email: lily.jeffery@zymecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

First commercially available product to utilize AstreAdept, Astrea Bioseparations\u2019 novel nanofiber-based membrane material CAMBRIDGE, England–(BUSINESS WIRE)–Astrea Bioseparations (\u201cAstrea Bio\u201d), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO\u2122 lentiviral vector (LVV) purification technology. Incorporating AstreAdept\u2122, the Company\u2019s proprietary nanofiber … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48984","6":"format-standard","7":"category-industry"},"yoast_head":"\nAstrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"First commercially available product to utilize AstreAdept, Astrea Bioseparations\u2019 novel nanofiber-based membrane material CAMBRIDGE, England–(BUSINESS WIRE)–Astrea Bioseparations (\u201cAstrea Bio\u201d), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO\u2122 lentiviral vector (LVV) purification technology. Incorporating AstreAdept\u2122, the Company\u2019s proprietary nanofiber ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T15:02:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220929005700\/en\/1587273\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification\",\"datePublished\":\"2022-09-29T15:02:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/\"},\"wordCount\":346,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005700\\\/en\\\/1587273\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/\",\"name\":\"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005700\\\/en\\\/1587273\\\/21\\\/Logo.jpg\",\"datePublished\":\"2022-09-29T15:02:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005700\\\/en\\\/1587273\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005700\\\/en\\\/1587273\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/","og_locale":"en_US","og_type":"article","og_title":"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification - Pharma Trend","og_description":"First commercially available product to utilize AstreAdept, Astrea Bioseparations\u2019 novel nanofiber-based membrane material CAMBRIDGE, England–(BUSINESS WIRE)–Astrea Bioseparations (\u201cAstrea Bio\u201d), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO\u2122 lentiviral vector (LVV) purification technology. Incorporating AstreAdept\u2122, the Company\u2019s proprietary nanofiber ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-29T15:02:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220929005700\/en\/1587273\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification","datePublished":"2022-09-29T15:02:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/"},"wordCount":346,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220929005700\/en\/1587273\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/","url":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/","name":"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220929005700\/en\/1587273\/21\/Logo.jpg","datePublished":"2022-09-29T15:02:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220929005700\/en\/1587273\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220929005700\/en\/1587273\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/astrea-bioseparations-introduces-nereus-lentihero-a-fit-for-purpose-solution-for-lentiviral-vector-purification\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48984"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48984\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}